This article was originally published on TipRanks.com Cytokinetics, Incorporated (NASDAQ: CYTK) received long-term funding capital from Royalty Pharma plc (RPRX) to support the commercial …
A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S.
The market is on the move, and this time stocks took off on an upward trajectory. On Wednesday April 29, all three of …
Written by Dan Cohen and Scott Matusow Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in …
The Good: Oppenheimer Sees Celsion Corporation Shares Soaring About 180% Over 12 Months It can be tricky putting a price tag on a …
Look out for the Street’s bearish stampede today where CYTK shares are crashing 31% in the aftermath of lead drug tirasemtiv’s failure.
Cytokinetics, Inc. (NASDAQ:CYTK) investors hit the panic button following the news that the drug maker is discontinuing development of tirasemtiv for amyotrophic lateral sclerosis …
H.C.
Mara Goldstein of research firm Cantor came out today with a bullish call on shares of Cytokinetics, Inc. (NASDAQ:CYTK).
In a research report released Friday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Cytokinetics, Inc. (NASDAQ:CYTK) with a price target of …
